Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Neurocrine Biosciences Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2022 / 07:50PM GMT
Release Date Price: $92.16 (+1.21%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

All right. Good afternoon, and welcome to the Barclays Global Healthcare Conference. My name is Carter Gould, Senior biopharma analyst here at Barclays. Pleased to welcome Neurocrine Biosciences to the stage.

We have Kevin Gorman, CEO; Matt Abernethy, CFO. Kevin, Matt, thanks very much for joining us here today. Really glad we could meet in person finally after a long period. We are overweight, Neurocrine, and very glad to have you guys today.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thank you very much, Carter, and thanks to Barclays for the invitation here. Really looking forward to -- good to see a lot of familiar faces. Before you start grilling me, I just wanted to say that we are going to be making forward-looking statements. So I would encourage you to look at our recent SEC filings.

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. And maybe, I might ask you just make a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot